Clinical trials: Patients with Multiple Sclerosis, open to volunteers
Relapsing Multiple Sclerosis
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany.
- Trial name
- AIOLOS (NCT05344469)
- Testing
- ofatumumab, glatiramer acetate, interferon β1
- Where
- 141 sites in Germany
- Volunteers
- 800 people
- Sponsor
- Novartis Pharmaceuticals
Stroke, Traumatic Brain Injury
Comparison of Gait Metrics in Patients With Stroke, Traumatic Brain Injury, and Multiple Sclerosis
People with neurological conditions often have difficulty walking, including problems such as foot drop. Functional electrical stimulation (FES) is a treatment that uses electrical signals to activate muscles and support walking.
- Conditions
- Stroke, Traumatic Brain Injury, Multiple Sclerosis
- Trial name
- NCT07492602
- Testing
- Functional Electrical Stimulation, Normal care
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Casa Colina Hospital and Centers for Healthcare
Spasticity
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral arbaclofen ER tablets in MS patients with spasticity.
- Trial name
- NCT05179577
- Testing
- Arbaclofen
- Volunteers
- 442 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Demyelinating Diseases of the Central Nervous System (DDC)
Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)
Demyelinating Diseases of the Central Nervous System Registry for Patients with Traditional Chinese Medicine (DATE-TCM) is an observational study aiming to better define the multidimensional (epidemiologic, demographic and…
- Trial name
- NCT05415579
- Testing
- Traditional Chinese medicine (TCM)
- Volunteers
- 2,000 people
- Sponsor
- Dongzhimen Hospital, Beijing
Non-Active Secondary Progressive Multiple Sclerosis
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible…
- Trial name
- TILS-022 (NCT06890923)
- Testing
- Foralumab TZLS-401 100 µg
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Tiziana Life Sciences LTD
Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
This study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod.
- Trial name
- NCT07732907
- Testing
- Ozanimod
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis, Myasthenia Gravis
- Trial name
- NCT07392528
- Testing
- QT-019C
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Huanhu Hospital
Multiple Sclerosis
Walking Fatigability,Saptiotemporal Gait Parameters and Falling in MS Patients
This observational study aims to investigate the relationship between walking fatigability, changes in spatiotemporal gait parameters, and risk of falling in individuals with multiple sclerosis (MS).
- Trial name
- WF-GAIT-FALL (NCT07524556)
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Ibrahim Ahmad Elmongy
Vaccine, Varicella-zoster Virus
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
Immunocompromised individuals, such as patients with multiple sclerosis (MS) or diseases of the neuromyelitis optica spectrum (NMOSD) treated with an anti-CD20 monoclonal antibody, present an increased risk of shingles.
- Conditions
- Vaccine, Varicella-zoster Virus, Multiple Sclerosis, Spectrum Disease Neuromyelitis Optica
- Trial name
- TACTIC (NCT07818356)
- Testing
- Two-dose M0-M2 vaccination schedule, Two-dose M0-M6 vaccination schedule
- Where
- 24 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Toulouse
Demyelinating Diseases
Use of a Portable Pupillometer to Detect Optic Nerve Impairment in Patients With Suspected Multiple Sclerosis
In the diagnosis work-up of inflammatory disorders of the central nervous system (CNS), the assessment of optic nerve impairments, even in the absence of clinical symptoms, is now systematic, as it may shorten the time to…
- Trial name
- IRIS (NCT07837050)
- Testing
- Pupillometry measures
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive…
- Trial name
- NCT07776743
- Testing
- Rocbrutinib, Dimethyl Fumarate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Multiple Sclerosis
Definition of Autonomic Nervous System Involvement in Patients With Multiple Sclerosis
The goal of this interventional non-pharmacological study is to evaluate the involvement of the autonomic nervous system in patients with relapsing-remitting and primary progressive multiple sclerosis.
- Trial name
- NCT05748015
- Testing
- quantification of sensory and autonomic small nerve fibers by punch skin biopsy, Cardiovascular Reflexes testing, Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Multiple Sclerosis, Pelvic Floor Dysfunction
Relationship Between Pelvic Floor Dysfunctions and Lower Limb Strength and Activation in MS Patients
we aim to investigate the relationship between pelvic floor dysfunctions, core endurance, hip external rotation muscle strength, and tibialis posterior and tibialis anterior muscle activation in patients diagnosed with MS
- Trial name
- NCT06777134
- Testing
- Assessment of pelvic floor dysfunction, The Quality of Life Assessment, Core endurance assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 73 people
- Sponsor
- Berivan Beril Kılıç
Multiple Sclerosis, Neuropathic Pain
OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis
This is an early phase safety evaluation of the use of oral extended release (OER) glibenclamide, which is otherwise known as glyburide, for use as a treatment for neurologic pain in people with multiple sclerosis.
- Trial name
- NCT07221799
- Testing
- glibenclamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Secondary Progressive Multiple Sclerosis (SPMS)
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
- Trial name
- REMASTER (NCT07225504)
- Testing
- Remibrutinib (blinded), Remibrutinib (Open label)
- Where
- 296 sites in United States, Argentina and 34 more
- Volunteers
- 1,275 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
- Trial name
- NCT05906992
- Testing
- CT-P53, US-Ocrevus, EU-Ocrevus
- Where
- Poland
- Volunteers
- 512 people
- Sponsor
- Celltrion
Hypogammaglobulinemia, Multiple Sclerosis
Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?
The investigators hypothesize that hypogammaglobulinemia (defined as IgG serum concentration <7.0g/L) is a treatable cause of fatigue in people with MS: The primary objective is to prove the link between hypogammaglobulinemia and…
- Conditions
- Hypogammaglobulinemia, Multiple Sclerosis, Fatigue
- Trial name
- FatIgG (NCT05357781)
- Testing
- Laboratory test
- Where
- Switzerland
- Volunteers
- 106 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Sclerosis
Transcranial Electrical Stimulation in Multiple Sclerosis
First the investigators will examine if the blood flow in the brain is different in patients with Multiple Sclerosis compared to healthy volunteers. HOW? The blood flow of the subjects is imaged by use of a special MRI-technique.
- Trial name
- TEMS (NCT06966128)
- Testing
- transcranial Direct Current Stimulation
- Where
- 2 sites in Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with…
- Trial name
- NCT07299019
- Testing
- Orelabrutinib
- Where
- 90 sites in United States, Australia and 18 more
- Volunteers
- 990 people
- Sponsor
- Zenas BioPharma (USA), LLC
Traumatic Brain Injury, Stroke
Remote Neuropsychological Assessment of Patients With Neurological Disorders and Injuries
For the last decades, many aspects of human life have been altered by digital technology. For health care, this have opened a possibility for patients who have difficulties travelling a long distance to a hospital to meet with…
- Conditions
- Traumatic Brain Injury, Stroke, Multiple Sclerosis, Parkinson Disease
- Trial name
- NCT05819008
- Testing
- Neuropsychological Assessment
- Where
- Sweden
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Umeå University